IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree
06 November 2023 - 2:00PM
Business Wire
IQVIA™ (NYSE:IQV), a global provider of data, analytics,
technology solutions and services to the life sciences industry,
announced that Dr. Christina Mack, chief scientific officer, has
been named to the 2023 PharmaVoice 100 list.
The PharmaVoice 100, an industry-acclaimed honor now in it’s
18th year, recognizes trailblazers and leaders who have built and
mentored innovative teams, developed breakthrough strategies, and
worked toward solutions that improve the lives of patients and
shape the future of life sciences.
“As our Chief Scientific Officer, Christina is passionate about
accelerating innovation in healthcare through the use of real world
data to enable evidence-based decision-making,” said IQVIA Chairman
and CEO Ari Bousbib. “She is consistently focused on moving our
industry forward, tackling challenges in a creative and innovative
way, and making a positive impact on patients and population
health.”
“This industry is a ground-breaking one capable of changing the
world through science and technology. Christina Mack and her fellow
honorees inspire advancements by guiding their teams, supporting
their patients, and propelling their organizations’ missions
forward. We are excited to recognize their contributions through
this annual list,” said Meagan Parrish, lead editor of
PharmaVoice.
Dr. Mack, an engineer and epidemiologist by training, was
recognized by her peers for her passion toward innovation, her
ability to form and mentor teams, and her scientific and technical
expertise. Also highlighted was her ability to balance science with
practical operations to achieve results, both through establishing
large, innovative programs as well as translating analytic results
to enable evidence-based decision-making. Dr. Mack’s work during
the COVID-19 pandemic was particularly impactful, illustrated by
her team’s recent UNIVANTS award for healthcare excellence
alongside the National Basketball Association (NBA) for their work
on the NBA Bubble and also through her global engagements with
elite U.S. sports leagues and the Tokyo 2020 Olympics.
“This award is an incredible honor, and reflects the brilliance
and hard work of the teams here at IQVIA as well as our clients and
partner organizations. The work we do together is pushing new
boundaries in science and technology to improve population health
and patient outcomes,” said Dr. Mack. “We are at such a critical
moment in our field, where science and technology are converging to
accelerate and improve healthcare. I am grateful to be in a place
where we are able to move the needle for patients and for our
industry.”
The 2023 PharmaVoice 100 honorees were celebrated during a
virtual two-day event PharmaVoice hosted with its sister
publication BioPharmaDive called “The Next Frontier of the Life
Sciences” on Oct. 25-26.
Read more about Dr. Mack’s recognition here.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 87,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106940706/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
IQVIA (NYSE:IQV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024